Open AccessChemotherapy resumption in ovarian cancer patient diagnosed with COVID-19
Author(s) -
Michalis Liontos,
Maria Kaparelou,
Emmanouil Karofylakis,
Dimitra Kavatha,
Αndreas Mentis,
Flora Zagouri,
Evangelos Terpos,
Meletios Α. Dimopoulos
Publication year - 2020
Publication title -
gynecologic oncology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.557
H-Index - 15
ISSN - 2352-5789
DOI - 10.1016/j.gore.2020.100615
Subject(s) - medicine , convalescence , chemotherapy , covid-19 , ovarian cancer , cancer , oncology , surgery , virology , disease , infectious disease (medical specialty) , outbreak
Highlights • Chemotherapy resumption after convalescence from COVID-19 is safe and feasible.• No guidelines exist for resumption of chemotherapy in patients with COVID-19.• Cancer patients on chemotherapy may develop SARS-CoV-2 antibodies less frequently.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom